Publications by authors named "Kylie M Konrath"
HIV Envelope (Env) is the main vaccine target for induction of neutralizing antibodies. Stabilizing Env into native-like trimer (NLT) conformations is required for recombinant protein immunogens to induce autologous neutralizing antibodies(nAbs) against difficult to neutralize HIV strains (tier-2) in rabbits and non-human primates. Immunizations of mice with NLTs have generally failed to induce tier-2 nAbs.
View Article and Find Full Text PDFArticle Synopsis
- - Ketamine is metabolized into various hydroxynorketamines (HNKs), with 12 unique forms identified; some of these, particularly (26)- and (26)-HNK, show quick antidepressant effects in tests on mice.
- - The study evaluated the pharmacokinetic profiles of all 12 HNKs, finding significant differences in how they reach and act in the brain, particularly noting the effectiveness of four specific (26)-HNKs in reducing immobility in the forced swim test.
- - Researchers hypothesized that the structure of the cyclohexanone ring in these HNKs influences their potency and created a modified version, (5)-methyl-(26)-HNK,
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune-focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses to infection and vaccines.
View Article and Find Full Text PDFMetabolism and pharmacokinetics characterization of metarrestin in multiple species.
Cancer Chemother Pharmacol
April 2020
Purpose: Metarrestin is a first-in-class pyrrolo-pyrimidine-derived small molecule targeting a marker of genome organization associated with metastasis and is currently in preclinical development as an anti-cancer agent. Here, we report the in vitro ADME characteristics and in vivo pharmacokinetic behavior of metarrestin.
Methods: Solubility, permeability, and efflux ratio as well as in vitro metabolism of metarrestin in hepatocytes, liver microsomes and S9 fractions, recombinant cytochrome P450 (CYP) enzymes, and potential for CYP inhibition were evaluated.